61. Autoimmune hemolytic anemia Clinical trials / Disease details
Clinical trials : 146 / Drugs : 131 - (DrugBank : 59) / Drug target genes : 28 - Drug target pathways : 158
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2100045594 | 2021-04-19 | 2021-04-19 | A single center prospective clinical study of Orelabrutinib in the treatment of relapsed/refractory autoimmune hemolytic anemia/Evans syndrome | A single center prospective clinical study of Orelabrutinib in the treatment of recurrent refractory autoimmune hemolytic anemia/Evans syndrome | Relapsed/refractory autoimmune hemolytic anemia /Evans syndrome | Single arm:Orelabrutinib; | Tianjin Medical University General Hospital | NULL | Recruiting | Both | Single arm:20; | Phase 4 | China |